Digoxin Marketing Rule Should Postpone Effective Date Two Years - Jerome
Executive Summary
FDA should postpone a digoxin marketing final rule effective date two years to allow sufficient time for manufacturers to file and receive NDA or ANDA approval for the cardiac drug, Jerome Stevens said in recent comments to the agency.
You may also be interested in...
Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years
Roxane Laboratories plans to submit an NDA for its digoxin elixir product in November, the company says
Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years
Roxane Laboratories plans to submit an NDA for its digoxin elixir product in November, the company says
Glaxo To File ANDA For Lanoxin Elixir, Requests Two-Years For Approval
GlaxoSmithKline plans to file an ANDA for Lanoxin Elixir using the tablet formulation of its cardiac drug Lanoxin (digoxin) as its reference drug.